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Background: Crohn's disease and ulcerative colitis are the major types of chronic inflammatory bowel disease
occurring in the colon and small intestine. A growing body of research has proposed that probiotics are able to
attenuate the inflammatory symptoms of these diseases in vitro and in vivo. However, the mechanism of probiotic
actions remains unclear.
Results: Our results suggested Lactobacillus plantarum MYL26 inhibited inflammation in Caco-2 cells through
regulation of gene expressions of TOLLIP, SOCS1, SOCS3, and IκBα, rather than SHIP-1 and IRAK-3.
Conclusions: We proposed that live/ heat-killed Lactobacillus plantarum MYL26 and bacterial cell wall extract
treatments impaired TLR4-NFκb signal transduction through Tollip, SOCS-1 and SOCS-3 activation, thus inducing LPS
tolerance. Our findings suggest that either heat-killed probiotics or probiotic cell wall extracts are able to attenuate
inflammation through pathways similar to that of live bacteria.
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Inflammatory bowel disease (IBD) comprises a collection
of disorders, which mainly include Crohn's disease and
ulcerative colitis. These disorders cause abdominal pain,
vomiting, diarrhea, and gastrointestinal (GI) inflamma-
tion [1]. To date, no effective therapy has been deve-
loped and patients may have a reduced quality of life
even under proper management. It has been shown that
factors related to IBD include acquired factors (e.g.,
smoking and diet), pathogens, genetic factors, and ir-
regular immune system [2]. Over the past decades, the
homeostatic functions of microflora on host GI tract
have attracted much attention because growing numbers
of clinical studies have suggested that probiotics ex-
hibit anti-inflammatory effects on IBD patients [3,4].
Arseneau et al. [5] suggested that innate immune re-
sponses play an equally significant, even more primary
character compared with adaptive immune responses in
IBD initiation and progression due to the observation
that probiotics elicit anti- inflammatory effects in the GI* Correspondence: mylin@dragon.nchu.edu.tw
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reproduction in any medium, provided the ortract by means of mucosal innate immune system stimu-
lation, instead of suppression. In this study, we put ef-
forts on addressing the interactions between probiotics
and intestinal epithelial cells, the mechanism different
from the conventionally dichotomous Th1/Th2 cytokine
paradigm.
Probiotics have no pharmacological actions confirmed,
but numerous benefits have been proposed, such as
immunomodulation [6,7], antioxidant capacities [8], he-
patoprotective effects [9], maintenance of commensal
microflora [10], pathogen antagonization [11], anti-
allergic effects [12,13] and decreased endotoxin level in
plasma [14]. Lactobacillus plantarum, one of the most
commonly used probiotics, is a member of the aeroto-
lerant group of lactobacilli found in several fermented
foods [15]. It is also one of the dominant Lactobacillus
species in the hosts’ intestinal tract. Recent studies have
shown that some strains of Lactobacillus plantarum
attenuate inflammation induced by Shigella flexneri
peptidoglycan by inhibiting nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB), inactiva-
ting mitogen-activated protein kinase (MAPK), and
reducing NOD2 mRNA expression as well as protein
levels, the actions which in turn lead to a decrease ind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Chiu et al. BMC Microbiology 2013, 13:190 Page 2 of 9
http://www.biomedcentral.com/1471-2180/13/190pro-inflammatory cytokine secretion [16]. Moreover, van
Baarlen et al. [17,18] demonstrated that even dead
L. plantarum can exert beneficial functions protecting
the host against the enormous array of commensal bac-
teria in the gut via epithelial crosstalk of mucosal inter-
face microbiota. Their research team further investigated
in vivo transcriptome responses to probiotics, the work
shaping that different probiotic strains induced differen-
tial gene-regulatory networks and pathways in the hu-
man mucosa [19]. This provides advanced concept that
not only live probiotics can exert beneficial effects, but
also dead probiotics are able to modulate GI homeosta-
sis. Second, because of strain-dependent properties, the
anti-inflammation mechanism of single strains could not
be extrapolated from other specific consequences with-
out empirical evidence.
Systemic exposure to endotoxins accompanied with
elevation of interleukin (IL)-6, IL-8 and IL-12 has been
recognized as representative features of IBD progression
[20,21]. Endotoxins are a family of molecules that bind
to many pattern recognition receptors. One of the most
dominant endotoxins is lipopolysaccharide (LPS). Previ-
ous exposure to LPS leads to cells hyporesponsive to
subsequent challenge with LPS. This phenomenon is
regarded as LPS tolerance.
LPS tolerance is typically associated with poor signal
transduction in TLR4-NFκB pathway. TLR4 recognizes
LPS from Gram-negative bacteria. Myeloid differenti-
ation primary response gene 88 (Myd88) acts as a uni-
versal adapter protein used by TLRs (except for TLR3).
Interleukin-1 receptor-associated kinase 1 (IRAK1) be-
longs to the serine/threonine protein kinase family. This
kinase mediates the TLR4 downstream signaling trans-
duction induced by LPS, forming a kinase complex
required for the activation of NFκB. TNF receptor asso-
ciated factor 6 (TRAF6) kinase mediates signal transduc-
tion from IRAK1, providing a link between IRAK1 and
Mitogen-activated protein kinase 7 (TAK1). TAK1 acti-
vate IκB kinase (IKK), and thus plays a role in relaying
signals to NFκB. IKK is an enzyme complex involved in
IκBα phosphorylation, the action that gives rise to NFκB
nuclear translocation [22].
It is well-studied that poor signal transduction in
TLR4-NFκB pathway is mainly attributed to negative
regulators [23]. Suppressors of cytokine signaling 1
(SOCS1) and suppressors of cytokine signaling 3 (SOCS3)
are able to reduce JAK/STAT signal transduction, involv-
ing negative feedback to cytokine signaling [24]. Toll
interacting protein (TOLLIP) interacts with many types of
TLR signaling downstream pathways and potently inhibits
the activity of IRAK after TLR activation. Overexpression
of TOLLIP has been reported to inhibit inflammation in
response to TLR4 signaling [25]. IL-1R-associated kin-
ase 3 (IRAK3) suppresses the dissociation of IRAK1/4from Myd88 and the connections among TRAF 6 com-
plexes [26]. Phosphatidylinositol-3,4,5-trisphosphate 5-
phosphatase 1 (SHIP1) hydrolyses phosphatidylinositol
3-kinase, hence interfering with TLR4-MyD88 signaling
pathway [27].
Since attenuation of pro-inflammatory cytokines secre-
tions is IBD therapeutic targets, In this study, we co-
cultured human epithelial colorectal adenocarcinoma
(Caco-2) cells with probiotics and then administered
LPS, which induced TNF-α, IL-6, IL-8 and IL-12 secre-
tion, to biologically mimic the inflammatory situation of
IBD. With the purpose of determining how L. plan-
tarum weakens the downstream signal transduction of
TLR4, the mRNAs that encode proteins participating in
TLR4-NF-κB pathway were detected by RT-qPCR. Five
negative regulator genes, SOCS1, SOCS3, TOLLIP, IRAK3
and SHIP1, which may result in inactivation of TLR4-
NF-κB pathway, were also examined whether or not to
be affected by probiotic treatment. Moreover, in order
to explore which cellular parts contribute mostly to
the anti-inflammatory properties, we tested the anti-
inflammatory efficacies of live bacteria, heat-killed
bacteria, cell wall extract, intracellular extract and
bacterial genomic DNA in terms of negative regulator
activation capacity.
Methods
Lactic acid bacterial strains
Isolation and identification of Lactobacillus plantarum
from newborn infant feces and breast milk were per-
formed in the Microbiology Laboratory of the Depart-
ment of Food Science and Biotechnology of National
Chung Hsing University, Taichung, Taiwan. Our prelim-
inary data showed L. plantarum MYL26, L. plantarum
MYL31, and L. plantarum MYL68 have better anti-
inflammation abilities than those of other strains isolated
in our laboratory.
Ethics statement
The samples from infants and adult subjects were ap-
proved employing in this study by Jeng-Yuan Hsu,
Chairman of Institutional Review Board of the Taichung
Veterans General Hospital. We obtained informed con-
sent from both adult subjects and these infants’ guar-
dians for collection of sample.
Preparation of cell wall, intracellular extracts and heat-
killed lactic acid bacteria
All bacterial strains used in this study were stored
at -80°C. Lactobacillus plantarum MYL26, Lactobacil-
lus plantarum MYL31, and Lactobacillus plantarum
MYL68 were cultured in MRS broth at 37°C for 16 h
and collected by centrifugation at 2500 g for 8 min.
For preparation of cell wall and intracellular extracts,
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deionized water and suspended in phosphate-buffered
saline (PBS). FRENCH® Pressure Cells Press (Thermo
Electron, Waltham, USA) was used for cell disruption.
Cell wall was removed by centrifugation at 5000 g for
10 min, and the supernatant was filtered through
0.22 μm filters as intracellular extract. The protein
contents of intracellular extracts were adjusted to
1 mg/mL. The weight of cell wall extracts processed
according to this protocol is about 10 ± 0.2 mg/107 cfu.
For preparation of heat-killed cells, cells were suspended
in PBS and adjusted to 107 cfu/mL followed by killing at
65°C for 30 min.
Preparation of bacterial genomic DNA
Lactic acid bacteria genomic DNA was extracted by tissue
and cell genomic DNA purification system (GeneMark,
Taichung, Taiwan). Nucleic acid concentration was
measured at a wavelength of 260 nm and adjusted to
10 μg/mL.
Cell culture
Human intestinal epithelial-like cells (Caco-2) were
obtained from the Bioresource Collection and Research
Center (BCRC, Hsinchu, Taiwan) and cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS), penicillin (100 units/mL) and streptomycin
(100 mg/mL) at 37°C in a humidified (95%) atmos-
phere with 5% CO2.
Cytokine secretions by stimulation of Caco-2 cells with
L. plantarum MYL26 followed by LPS challenge
Caco-2 cells (106 cells/mL) were treated with live L.
plantarum MYL26 (107 cfu/mL), heat-killed bacteria
(107 cfu/mL), intracellular extracts (100 μg/mL), cell
wall extracts (10 ± 0.2 mg/mL) and genomic DNA
(1 μg/mL) at 37°C for 10 hours. After stimulation,
cells were challenged with 1 μg/mL LPS for 18 hours.
The supernatants were removed and IL-6, IL-8, IL-
12p70 and TNF-α secretions were assayed by enzyme-
linked immunosorbent assay (eBioscience ELISA system,
California, USA).
siRNA silencing technique
Silencing of human SOCS1, SOCS3 and TOLLIP ex-
pressions was carried out in Caco-2 cells by using
Dharmacon Human siGENOME® SMARTpool® siRNA
Libraries for antisense oligonucleotides (AO) design. AO
were transfected with DharmaFECT 2 reagent (Thermo
Fisher Scientific, Massachusetts, USA) according to the
manufacturer’s instructions. The siRNA experiment was
conducted for 48 h and cells were collected to analyze
total RNA for knockdown effect.RT-qPCR
RNA isolation was conducted using EZ-RNA total RNA
isolation kit (Biological Industries, Beit Haemek, Israel).
Reverse transcription was carried out according to man-
ufacturer’s instruction (Bio-Rad iScript™ cDNA synthesis
kit, USA). Comparisons of gene expressions via qPCR
were performed by adopting the following primer de-
signs: SOCS3 (5′-CAA ATG TTG CTT CCC CCT TA-
3′ and 5′-ATC CTG GTG ACA TGC TCC TC-3′),
SHIP1 (5′-TCC AGC AGT CTT CCT CAC CT-3′ and
5′-GCT TGG ACA CCA TGT TGA TG-3′), IRAK3 (5′-
GGG TGC CTG TAG CAG AGA AG-3′ and 5′-ATC
TGG AGG AGC CAG GAT TT-3′), SOCS1 (5′-CTG
GGA TGC CGT GTT ATT TT-3′ and 5′-TAG GAG
GTG CGA GTT CAG GT-3′), TOLLIP (5′-CCA CAG
TGT GAG GGA TTG TG-3′ and 5′-TCT CCT TCT
CAT GCC GTT CT-3′), MyD88 (5′-GCA CAT GGG
CAC ATA CAG AC-3′ and 5′-GAC ATG GTT AGG
CTC CCT CA-3′), IKKβ (5′-GCT GCA ACT GAT
GCT GAT GT-3′ and 5′- TGT CAC AGG GTA GGT
GTG GA-3′), TAK1 (5′-TTT GCT GGT CCT TTT
CAT CC-3′ and 5′-TGC CCA AAC TCC AAA GA
ATC-3′), TLR4 (5′-TGA GCA GTC GTG CTG GTA
TC-3′ and 5′-CAG GGC TTT TCT GAG TCG TC-3′),
IκBα (5′-GCA AAA TCC TGA CCA GGT GT-3′ and
5′-GCT CGT CCT CTG TGA ACT CC-3′), GAPDH
(5′-GAG TCA ACG GAT TTG GTC GT-3′ and 5′-
TTG ATT TTG GAG GGA TCT CG-3′), TRAF6 (5′-
CTG CAA AGC CTG CAT CAT AA-3′ and 5′-GGG
GAC AAT CCA TAA GAG CA-3′), IRAK1 (5′-GGG
TCC AGG TGC TTC TTG TA-3′ and 5′-TGC TAG
AGA CCT TGG CTG GT-3′). Quantitative PCR was
carried out according to the manufacturer’s protocol.
After reverse transcription of mRNA, 5 μl of the re-
verse transcription product were added to a BioRad
iCyclerTM PCR system containing 0.3 μM of each
primer. One-fold QuantiTect SYBR Green PCR Master
Mix was used as a fluorescent reporter (QuantiTect
SYBR Green PCR, Qiagen). The condition was pro-
grammed as follows: (1) Denaturation at 94°C for
10 min; (2) Amplification for 40 cycles of denatura-
tion at 94°C for 15 s, annealing at 55°C for 30 s, and
extension at 72°C for 20 s.
Cell viability assay
3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium
bromide (MTT) assay, which is based on the cleavage of
the tetrazolium salt by mitochondrial dehydrogenases in
viable cells. In order to determine toxicity concentration,
approximately 105 cells were plated onto each well of
96-well plates for 24 h, followed by treatment with dif-
ferent probiotic agents for 6, 8, 10, 12 and 14 hours.
After incubation, 200 mL of MTT solution (0.5 mg/mL)
were added to each well for 4 h after washing by PBS.
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methyl sulphoxide (DMSO) were added to each well to
dissolve the dark blue formazan crystals. The absorbance
was measured by ELISA plate reader (Jupiter, ASYS
Hitech, Austria) at 570 nm. To compare the results, the
relative cell viability was expressed as the mean percent-
age of viable cells compared with untreated cells (100%).
Statistical analysis
Each value is the mean of triplicate experiments in each
group. Means comparison was carried out by Student's
t-test. P < 0.05 was considered significantly different.
Results
Lactobacillus plantarum MYL26/ MYL31/ MYL68 treatment
did not affect the Caco-2 cell viability within 10 hours
Due to excellent lactic acid production capacities of
Lactobacillus plantarum, we perform MTT assay to as-
sess the most appropriate incubation time. As Figure 1
showed, cell viability was not influenced within 10 hours.
Incubated with 12 and 14 hours, Caco-2 cell viability
showed significant decrease. As a result, we co-cultured
Caco-2 cells and Lactobacillus plantarum for 10 hours
in the following experiments.
Lactobacillus plantarum attenuates LPS-induced cytokine
secretion
Three different strains of Lactobacillus plantarum
(MYL26, MYL31 and MYL68) were tested and the most
potent strain, in terms of refractoriness to subsequent
LPS stimulation, was selected. As shown in Figure 2, L.
plantarum MYL26 attenuated TNF-α, IL-6, IL-8, andFigure 1 Approximately 1 × 105 cells were plated onto 96-well plates
L. plantarum MYL26 (L. plantarum MYL31/ MYL68 data not shown) an
* represents P-value smaller than 0.05 analyzed by t-test in comparison wit
not treated with probiotics.IL-12 production more effectively than those of other
strains.
Lactobacillus plantarum MYL26 attenuates downstream
signal transduction of TLR4-NFκB pathway
The results of RT-qPCR (Figure 3) indicated that there
are no significant differences in the expressions of TLR4,
MyD88 and IRAK1 in comparison with those of LPS
treatment group. The expressions of TRAF6, TAK1 and
IKKβ decreased more significantly under L. planta-
rum MYL26 treatment than those under LPS treat-
ment alone.
Lactobacillus plantarum MYL26 pretreatment elicits
anti-inflammatory properties by enhancing the
expressions of TOLLIP, SOCS1 and SOCS
Since TRAF6, TAK1 and IKKβ were down-regulated, five
potential negative regulator gene expressions were ex-
amined. As shown in Figure 4, there were no consider-
able differences in the expressions of IRAK3 and SHIP1
while the expressions of TOLLIP, SOCS1 and SOCS3
were higher than those in the control groups.
TOLLIP, SOCS1 and SOCS3 knockdown gave rise to
impaired anti-inflammation abilities
We then used gene knockdown technique to silence
TOLLIP, SOCS1 and SOCS3. Prior tests have shown that
silencing of target genes does not decrease the expres-
sion of non-target genes (Figure 5). TOLLIP, SOCS1 and
SOCS3 were silenced separately and subsequently chal-
lenged by LPS. The silencing of these three genes
resulted in the partial loss of anti-inflammatory function
of L. plantarum MYL26 (Figure 6).for 24 h, followed by treatment with live/ heat-killed
d different cellular parts for 6, 8, 10, 12 and 14 hours. Symbol
h negative control group. (n = 3). Negative control: Caco-2 cells were
Figure 2 Caco-2 cells (106 cells/mL) were treated with live L. plantarum MYL26/ MYL31/ MYL68 (107 cfu/mL) at 37°C for 10 hours,
followed by 1 μg/mL LPS challenge. Negative control: Caco-2 cells were not treated with LPS and probiotics. (Cytokine secretion baseline).
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SOCS1/3, TOLLIP and IκBα expression might be located in
the cell walls
To investigate the involvement of different cellular parts
in reducing LPS-induced inflammation, live bacteria,
heat-killed bacteria, cell wall extract, intracellular extract
and bacterial genomic DNA were tested to assess which
cellular parts activate TOLLIP, SOCS1, SOCS3 and IκBα.
The results showed that dead L. plantarum MYL26 acti-
vate gene expressions as well as live bacteria. Cell wall
extract, intracellular extract and genomic DNA alsoFigure 3 Caco-2 cells (106 cells/mL) were treated with live L. plantaru
LPS challenge. Gene expressions were assayed by RT-qPCT normalized by
t-test in comparison with negative control group. (n = 3). Negative control:
with probiotics.stimulated gene expression, but not as well as the whole
cell (Figure 7).
Discussion
Almost all of the IBD medicines are associated with de-
crease of inflammation signal pathways. On the other
hand, pro-inflammatory cytokines play imperative char-
acter in mediating the progression of IBD. Numerous
clinical trials have shown that better control of pro-
inflammatory cytokine production is an essential method
for improving symptoms [28-30].m MYL26 (107 cfu/mL) at 37°C for 10 hours followed by 1 μg/mL
GAPDH. Symbol * represents P-value smaller than 0.05 analyzed by
Caco-2 cells were challenged by LPS without pretreatment
Figure 4 Caco-2 cells (106 cells/mL) were treated with live L. plantarum MYL26 (107 cfu/mL) at 37°C for 10 hours. Gene expressions were
assayed by RT-qPCR normalized by GAPDH. Symbol * represents P-value smaller than 0.05 analyzed by t-test in comparison with negative control
group. (n = 3). Negative control: Caco-2 cells were not treated with probiotics.
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molecular patterns (PAMPs), the epithelial cells act as
the first barrier of defense against invading microbes.
Intestinal epithelial cells take part in mediating ba-
lanced immune actions, as well as stimulating immune
cells that dwell in the lamina propria. In this respect,
Baumgart et al. [31] suggested that IBD results from a
collapse of tolerance towards the commensal microbiota.
An aberrant LPS response results in an inflammatory
phenotype. As a consequence, elevated attention to
probiotics for the treatment of GI tract disorders has
shed light on new therapeutic regimens.Figure 5 Human SOCS1, SOCS3 and TOLLIP gene expressions
were not off-targeted. The siRNA experiment was conducted
for 48 h.LPS tolerance may occur as the host’s defense system
that confines an inflammatory break upon successive
stimulation [32]. In our study, it is expected to reveal
the mechanism by which prolonged contact of lactic acid
bacteria with intestinal epithelial cells leads to hypore-
sponsive to the following inflammatory stimuli. It helps
establish a probiotic screen criteria for selection of the
best LPS tolerance induction bacterial strains, rather
than traditional criteria focused on bile-acid resistant
ability.
Until now, many possible anti-inflammatory mecha-
nisms of probiotic actions have been proposed and it is
observed that probiotic effect is both strain dependent
and dose dependent [33]. Although different strains of
lactic acid bacteria possess different properties, there
have been the most publications reported on L. plan-
tarum when searching by key words “dead probiotics” or
”killed probiotics”. As a result, we examined three differ-
ent strains of L. plantarum and used the most potent
strain MYL26, as a study object researching the under-
lying molecular mechanisms.
In this research, upon L. plantarum MYL26 treatment,
the expression of genes that encode proteins participat-
ing in LPS-induced inflammation was compared with
that of untreated group and found that TRAF6, TAK1
and IKKβ expressions were suppressed. We also observed
that expression of IκBα was increased. It was perhaps at-
tributed to prior probiotic stimulation on Caco-2 cells, the
action that caused mild inflammation (data not shown) as
well as slightly NFκB nuclear translocation which encoded
not only cytokines but also IκBα. This observation was
similar to the results Wahlstrom et al. reported [34]. They
suggested that low-dose LPS pretreatment changed sub-
sequent LPS-activated signal transduction pathways by
Figure 6 TOLLIP, SOCS1 and SOCS3-silenced Caco-2 cells (106 cells/mL) were treated with live L. plantarum MYL26 (107 cfu/mL) at
37 ±°C for 10 hours, followed by 1 μg/mL LPS challenge. Negative control: Caco-2 cells were not treated with LPS and probiotics.
(Cytokine secretion baseline).
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control inhibitor.
Since the results showed that anti-inflammatory effects
of L. plantarum MYL26 on Caco-2 might be through
interfering with TLR4 downstream pathway, it is rea-
sonable to infer that the activation of the negative
regulators of TLR4-NFκb pathway contributes to the
anti-inflammatory effect. We investigated TLRs-associated
negative regulators, including TOLLIP, SOCS1, SOCS3,
IRAK3 and SHIP1, and found TOLLIP and SOCS1/3Figure 7 The candidate anti-inflammation gene expressions were ind
cells (106 cells/mL) were treated with live L. plantarum MYL26 (107 cfu/mL)
cell wall extracts (10 ± 0.2 mg/mL) and genomic DNA (1 μg/mL) at 37°C fo
t-test in comparison with negative control group. (n = 3). Negative control:expressions were enhanced by L. plantarum MYL26
treatment. However, the consequence that TOLLIP
and SOCS1/3 knockdown gave rise to impaired anti-
inflammatory ability further supported the hypothesis
that activation of the negative regulators of TLR4-NFκb
pathway is a primary exploit for the anti-inflammatory ef-
fect L. plantarum MYL26 exerts. As numerous literatures
have revealed that different components of the bacterial
cells can result in different activities on the human GI
tract, such as cell wall components [35], genomic DNAuced in different degrees by diverse cellular components. Caco-2
, heat-killed bacteria (107 cfu/mL), intracellular extracts (100 μg/mL),
r 10 hours. Symbol * represents P-value smaller than 0.05 analyzed by
Caco-2 cells were not treated with probiotics.
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the TOLLIP and SOCS1/3 activation ability of live/ heat-
killed whole bacterial cells, cell wall extract, intracellular
extract and genomic DNA from L. plantarum MYL26 to
see which cellular parts contributed mostly to LPS tole-
rance induction.
In contrast with our expectations, although intracellu-
lar extract and genomic DNA induced IκBα expression
more significantly than that of control group, they failed
to activate TOLLIP, SOCS1, and SOCS3. There are five
TLRs (TLR2/ 4/ 5/ 7/ 9) sharing similar downstream
signal pathway (MyD88, IRAK, TRAF, IKK, NFκb) [38].
Except for IκBα which directly binds to NFκb, the
negative regulators TOLLIP, SOCS1, and SOCS3 are
well-established having abilities in interference with re-
cruitment of MyD88 and IRAK. It has been reported
that TOLLIP, SOCS1, and SOCS3 not only attenuate
TLR4 signaling, but also have impact on TLR2/5/7/9 sig-
naling [39,40]. Briefly, L. plantarum MYL26 intracellular
extract and genomic DNA activate TLRs-NFκb path-
ways other than TLR4 (TLRs cross-tolerance), but
they did not attenuate inflammation through induc-
tion of TOLLIP, SOCS1, and SOCS3. Taken together,
we proposed that L. plantarum MYL26 intracellular
extract and genomic DNA induced LPS tolerance
through pathways different from induction of Tollip,
SOCS-1 and SOCS-3, which were key negative regula-
tors activated by live/dead L. plantarum MYL26 and
cell wall components.
One of the limitations of this study is that the causes
of IBD, other than breakdown of LPS tolerance, are
multifaceted. Several lines of evidence has pointed out
that in addition to inherited factors, pollution, drugs, di-
ets, breastfeeding, even emotional stress, could be re-
sponsible for genetically failing to interpret molecular
microbial patterns appropriately, thus leading to irregu-
lar innate and adaptive immune responses [41,42]. The
second limitation is that PAMPs other than LPS induce
GI inflammation through different pathways. Criteria for
probiotic selection of LPS tolerance induction strains
might be not suitable with respect to inflammation symp-
toms caused by other PAMPs.
Conclusions
The administration of lactic acid bacteria in patients suf-
fering from GI disorders regularly depends on try-error
methods, and numerous probiotics treatment applied to
clinical trials showed frustrated results, which perhaps
might be related to the fact that the probiotic screening
criteria is generally based on susceptibility to artificial GI
environments (acid and bile resistance) or adhesive
properties instead of on immunomodulatory capacities,
for instance, induction of LPS tolerance. Our research
provided a new insight to describe the L. plantarumstrain-dependent characterization in terms of anti-
inflammatory effects, and suggested an essential role for
Lactobacillus plantarum and Lactobacillus plantarum-
derived constituents in the induction of LPS tolerance.
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